Taiwan Resonant Waves Research

Executive Summary

Taiwan Resonant Waves Research (TRWR) is a Taiwanese med-tech company pioneering non-invasive bioelectronic medicines for chronic metabolic, immune, and neurological disorders. Its wearable device platform delivers targeted electrical stimulation to modulate nerve and cellular activity, aiming to treat conditions such as diabetes, inflammatory bowel disease, pain, and sleep disorders. Founded in 2010 and currently in Phase 2 clinical development, TRWR differentiates itself through a proprietary closed-loop stimulation algorithm that adapts therapy in real-time. The company has positioned itself at the intersection of neuromodulation and digital therapeutics, with a focus on diseases where conventional pharmacological options have limited efficacy or significant side effects. TRWR's platform offers potential advantages in safety, tolerability, and patient compliance due to its non-invasive nature. While still in the clinical stage, the company has demonstrated proof-of-concept in earlier trials and is now advancing pivotal studies. With a growing body of evidence supporting the role of electrical stimulation in modulating inflammatory and metabolic pathways, TRWR is well-placed to capture value in the rapidly expanding bioelectronic medicine market. The company's success hinges on successful completion of ongoing trials, securing strategic partnerships, and navigating regulatory pathways in Taiwan, the United States, and other key markets.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data for diabetes indication60% success
• Q2 2026Strategic partnership with global pharmaceutical company50% success
• Q1 2026FDA Breakthrough Device Designation40% success